# EPDBIO Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epdbio-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.epdbio.com
- Latest round: Seed (Oct 1, 2021)
- Investors on record: 2

## About

Founded in 2021, and based in Seoul, South Korea, EPDBIO Co., Ltd., also known as EPD Biotherapeutics Inc., operates as a biotechnology company. The company was founded by its CEO, Jae-Hyun Choi. In June 2022, EPD Biotherapeutics Inc. raised KRW 4.4 billion in pre-series A from FuturePlay, Hana Ventures, and Mirae Asset Venture Investment.

EPD Biotherapeutics offers a bioPROTAC platform, which is an engineered protein degraders (EPDegTM) platform that combines two specialties: targeted protein degradation biology and antibody/protein engineering. This allows EPD Bio to develop novel and effective therapeutic modalities and targeted protein degradation agents for a wide range of diseases. The firm’s targeted protein degradation (TPD) platform uses biologics such as antibodies, proteins, and peptides to develop new therapies, and the platform is based on the discovery of certain proteins called E3 ubiquitin ligases. The company’s pipeline project includes EPD-101, EPD-201, and EPD-301.

## Funding rounds

- Seed, Oct 1, 2021 — FuturePlay, Korea Tech Incubator for Startup
- Seed, Sep 1, 2021 — FuturePlay

## Investors

- FuturePlay (https://capitalatlas.ai/funds/futureplay) — Seed
- Korea Tech Incubator for Startup — Seed